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ABSTRACT
Glucocorticoids (GCs) inhibit the resorptive capacity of the osteoclast by disrupting its cytoskeleton. We find that calpain-6 (Capn6), a
unique, nonproteolytic member of its family, is suppressed 12-fold by dexamethasone (DEX) in the bone-degrading cell. While Capn6
abundance parallels commitment of naive bone marrow macrophages (BMMs) to the osteoclast phenotype, its excess or deletion does
not affect the cell’s differentiation. On the other hand, Capn6 localizes to the sealing zone, and its overexpression promotes osteoclast
spreading and large actin ring formation, eventuating in stimulated bone degradation. Conversely, Capn6 knockdown impairs
cytoskeletal organization and the cell’s resorptive capacity. Capn6 complexes with tubulin, and its absence inhibits microtubule
acetylation and stability in the osteoclast. Knockdown of Capn6 also reduces b3-integrin subunit protein, another essential regulator of
osteoclast cytoskeletal function. Reflecting Capn6 as a target molecule of GCs, microtubule stability and acetylation, as well as the
expression of b3-integrin protein, are similarly suppressed in DEX-treated osteoclasts. Moreover, overexpression of Capn6 rescues GC-
mediated disruption of osteoclast cytoskeleton. Thus Capn6 promotes cytoskeletal organization and microtubule stability in osteoclasts,
and its inhibition may mediate the resorption-arresting properties of GCs.  2011 American Society for Bone and Mineral Research.
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Introduction
S
keletal remodeling is an ever-occurring event in mammals
and likely serves to replace effete bone with new. Hence
agents such as glucocorticoids (GCs), which suppress remodel-
ing, predispose to fracture.
Remodeling is initiated by bone resorption, which is tethered
to bone formation. Thus inhibition of osteoclast activity is typi-
cally attended by parallel changes in the osteoblast. In this
regard, the suppressed remodeling attending GC therapy is
initiated by inhibited osteoclast function consequent to the cell’s
inability to organize its cytoskeleton. Since stimulated remodel-
ing is the most successful approach to treating GC-induced
osteoporosis,
(1) identifying the means by which steroids blunt
the osteoclast is therapeutically relevant.
The osteoclast cytoskeleton is unique, and its organization is
initiated by contact with bone. In this circumstance, the cell
polarizes and generates sealing zones or actin rings that isolate
the resorptive microenvironment from the general extracellular
space.
(2) These polarizing events require an intact microtubule
network, reflecting, in turn, appropriate tubulin acetylation.
(3,4)
For example, Pyk2
–/– osteoclasts are unable to produce actin
ringsasaresultofimpairedmicrotubuleacetylationandstability,
prompting increased bone density.
(5) Osteoclast cytoskeletal
organizationalsodependsonligationandactivation ofthe avb3-
integrin.
(6,7) Thus failure to express or activate avb3-integrin
compromises cell spreading and actin ring formation and
consequently arrests resorption.
(6,7)
We performed microarray analysis of GC-treated osteoclasts
and found calpain-6 (Cpan6), a candidate cytoskeleton effector
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657molecule. Classic calpains are calcium-dependent cysteine
proteases
(8–12) that participate in integrin-mediated cytoskeletal
organization during migration. These enzymes cleave a number
of cytoskeleton-associated proteins including talin, paxillin,
tubulin, Src, Pyk2, and the b3-integrin subunit.
(13–23) These
calpain substrates are enriched in the osteoclast actin ring, and
the classic calpains, Capn1 (m-calpain) and Capn2 (m-calpain),
regulateosteoclastmotilityandboneresorptionbycleavingtalin
and Pyk2.
(16) Unlike the classic calpains, Capn6 does not possess
an active-site catalytic cysteine residue and therefore is likely not
a functional protease.
(24) Capn6, however, is biologically relevant
becauseit isanendothelin-1 (ET-1)target involvedinpharyngeal
arch development.
(25) Importantly, RNAi-mediated inactivation
of Capn6 in transformed cells causes microtubule instability and
enhances lamellipodium formation.
Whether Capn6 influences the osteoclast was heretofore
unknown, but we found that it was expressed with differentia-
tion and repressed by dexamethasone (DEX). Furthermore,
Capn6 overexpression in the resorptive polykaryon accelerates
microtubule acetylation and cytoskeletal organization. Conver-
sely,Capn6knockdownarrestsmicrotubuleacetylationandactin
ring formation as well as diminishing b3-integrin protein.
Similarly, DEX destabilizes microtubules and reduces b3-integrin
protein expression. Capn6 therefore regulates microtubule- and
integrin-associated organization of the cytoskeleton in osteo-
clasts, and its inhibition may be a means by which GCs suppress
bone remodeling.
Materials and Methods
Macrophage isolation and osteoclast culture
Primary bone marrow–derived macrophages (BMMs) were
prepared as described previously.
(26) Briefly, the marrow was
extracted from the tibias and femurs of 6- to 8-week-old C57/BL6
mice with a-minimal essential medium (a-MEM) and cultured for
3 days with a-MEM containing 10% fetal bovine serum (FBS) and
1/10volumeofCMG14-12culture supernatant.
(27)Thecellswere
lifted with 1  trypsin/EDTA, plated in a 96-well culture plate at a
density of 5 10
3 cells/well, and cultured in a-MEM containing
10% FBS in the presence of 100ng/mL of receptor activator of
nuclear factor kB ligand (RANKL) and 10ng/mL of macrophage
colony-stimulating factor (M-CSF). Cultured cells were fixed in
10% formaldehyde for 10minutes and then 12.5mM citrate
buffer containing acetone (65%) and formalin (2.96%) for 1
minute. Osteoclasts were stained for tartrate-resistant acid
phosphatase (TRAP) activity. For DEX treatment, BMMs were
cultured in M-CSF and RANKL for 3 days to commit them to
the osteoclast phenotype. The cells then were treated with
vehicle or DEX (100 nM) for 2 days in the presence of RANKL and
M-CSF.
RT-PCR
Total RNA (1 mg) extracted from cultured cells was used as a
template for cDNA synthesis. Primers were synthesized on the
basis of the reported mouse cDNA sequence. The following
primers were used for Capn1 (sense, 5’-CGAGCCCAACAAA-
GAAGG-3’; antisense, 5’-CGCACAAGACAGCACACAA-3’), Capn2
(sense, 5’-ACATCCACCTCGGCAAAA-3’; antisense, 5’-CCACTCC-
CATCTTCATCCA-3’), Capn5 (sense, 5’-GCCATTCCAACTCCAAAAA-
3’; antisense, 5’-GCCCATCTTCTCCCTCTCAC-3’), Capn6 (sense, 5’-
TCTTCTCATTCTCCACCTCCA-3’; antisense, 5’-GCCACTCCATTCCT-
GTCTTC-3’), b3-integrin (sense, 5’-TTACCCCGTGGACATCTACTA-3’;
antisense, 5’-AGTCTTCCATCCAGGGCAATA-3’), Atp6V0d2 (sense,
5’- TAGCCAAGTGTCACCCACTG-3’; antisense, 5’- TGATGATTAAA-
GCGCGTCTG-3’), DC-STAMP (sense, 5’- CGTGGAGAGAAGCAAG-
GAAC-3’; antisense, 5’-CAGCCTTGCAAACTCAAACA-3’), TRAP
(sense, 5’-ACAGCCCCCCACTCCCACCCT-3’; antisense, 5’-TCAGG-
GTCTGGGTCTCCTTGG-3’), MMP9 (sense, 5’-CCTGTGTGTTCCC-
GTTCATCT-3’; antisense, 5’-CGCTGGAATGATCTAAGCCCA-3’),
cathepsin K (sense, 5’-GGAAGAAGACTCACCAGAAGC-3’; anti-
sense, 5’-GTCATATAGCCGCCTCCACAG-3’), and GAPDH (sense,
5’-ACTTTGTCAAGCTCATTTCC-3’; antisense, 5’-TGCAGCGAACTT-
TATTGATG-3’). Amplification was conducted for 22 to 31 cycles,
each of 948C for 30seconds, 558C for 30seconds, and 728C for
30seconds. Ten microliters of each reaction mixture was
analyzed by 1.5% agarose gel electrophoresis.
Retroviral transduction
Capn6 was cloned into pMX retroviral vector containing Flag and
transfected into Plat-E packing cells (a gift from S Takeshita)
using Transfectol (Gene Choice, Frederick, MD, USA). Virus was
collected from cultured medium 24 to 48hours after transfec-
tion. BMMs were transduced with virus for 24hours in the
presence of 4 mg/mL of Polybrene (Sigma-Aldrich, St Louis, MO,
USA). Cells then were selected with 1 mg/mL of blasticidin
(Calbiochem, San Diego, CA, USA) for 3 days.
Lentiviral transduction of Capn6 shRNA
Oligonucleotides encoding a target site for Capn6 and loop RNA
were cloned into lentiviral vector. The lentiviruses encoding
luciferase shRNA (Luc-sh) were used as a control. The sense
sequences for Capn6-sh1 and Capn6-sh2 were 5’-GGACCACT-
GACATTCCTATTA-3’ and 5’-GGTTCCGTCTTCACCATCTGTA-3’,
respectively. Recombinant lentiviral production was carried
out according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). Briefly, the 293T producer cell line was
cotransfected with the expression constructs and packaging
mixture. The viral supernatant was harvested after 48hours.
BMMs were transduced with viral supernatant plus 10 mg/mL of
protamine sulfate (Sigma-Aldrich) for 24hours. Cells then were
selected in the presence of 4 mg/mL of puromycin for 5 days.
Western blot analysis and immunoprecipitation
Cells were harvested in lysis buffer (10mM Tris, pH 7.4, 150mM
NaCl, 1% NP-40, 1mM EDTA, and 10% glycerol) containing
protease and phosphatase inhibitor. After incubation on ice for
10minutes, the cell lysates were clarified by centrifugation at
14,000rpm for 30minutes. The protein concentration was
measured with a Bicinchoninic Acid Kit (Pierce, Rockford, IL,
USA), and an equal amount of each lysate was separated on an
SDS-polyacrylamide gel. After the proteins were transferred to a
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica,
MA, USA), the membrane was blocked and incubated with
primary antibodies. Monoclonal antibodies to FLAG M2 and
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Aldrich. Polyclonal antibodies to Capn6 were from Abcam
(Cambridge, MA, USA) or Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Monoclonal antibody to a-tubulin was from Abcam. All
antibodieswerediluted1:1000.Proteinswerevisualizedusingan
appropriate secondary antibody. This was followed by an
application of enhanced chemiluminescence reagents.
For the immunoprecipitation, cells were harvested with lysis
buffer (10mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, 1mM EDTA,
and 10% glycerol) containing protease and phosphatase
inhibitors. The lysates were immunoprecipitated with anti-a-
tubulin antibody followed by incubation with protein A/G-
Sepharosebeads (Pierce)at48Candanalysis byimmunoblotting.
Actin ring formation and bone resorption assay
BMMs were cultured on bone with RANKL (100ng/mL) and M-
CSF (10ng/mL). Cells were fixed in 4% paraformaldehyde and
permeabilized in 0.1% Triton X-100. After washing with PBS, cells
were stained for actin with 10 mg/mL of Tetramethyl Rhodamine
Isothiocyanate (TRITC)-conjugated phalloidin (Sigma-Aldrich).
For the staining of resorption pits, cells were removed from bone
sliceswithmechanicalagitation. Boneslices wereincubated with
20 mg/mL of peroxidase-conjugated wheat germ agglutinin for
45minutes. After washing with PBS, 3,3’-diaminobenzidine
(Sigma-Aldrich) was added onto the bone slices. To quantify
the osteoclast bone resorption, the level of type I collagen
fragments (CTX-1) was assayed using CrossLaps ELISA (Nordic
Bioscience Diagnostics, Herlev Denmark), as described pre-
viously.
(26)
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 20minutes and
permeabilized with 0.1% Triton X-100, followed by blocking with
0.2% bovine serum albumin (BSA) for 10minutes. Specific
proteins were labeled with the following primary antibodies: the
goat polyclonal anti-Capn6 antibody (diluted 1:50; Santa Cruz),
monoclonalanti-FLAG M2andanti-acetylated tubulinantibodies
(diluted 1:100; Sigma), and anti-a-tubulin antibody (diluted
1:100; Abcam). After washing with PBS, secondary antibody was
added for 1 hour at room temperature and then washed with
PBS three times. Samples were mounted with 90% glycerol in
PBS and observed using a confocal microscope (LSM, Carl Zeiss,
Jena, Germany). All images from the same set of experiments
were taken without changing the camera settings.
Statistics
All data are presented as mean SD. Statistical significance was
determined by two-tailed Student’s t test.
Results
Capn6 is a GC target upregulated during
osteoclastogenesis
To identify GC targets, we committed precursors to the
osteoclast phenotype by 3 days of exposure to M-CSF and
RANKL. The cells were treated with vehicle or DEX for 16hours in
osteoclastogenic medium containing charcoal-stripped FBS.
Microarray analysis demonstrates that Capn6 is decreased
12.8-fold in osteoclasts exposed to the steroid (data not shown).
Confirming the relevance of this observation, Capn6 mRNA and
protein are reduced by DEX treatment (Fig. 1A).
To determine the expression pattern of calpain family proteins
during osteoclast formation, BMMs were exposed to osteoclas-
togenic cytokines. While the classic calpains (Capn1 and -2) and
Capn5 mRNAs are expressed constitutively but not induced,
Capn6 mRNA increases as the cells differentiate (Fig. 1B).
Similarly, Capn6 protein accumulates incrementally throughout
the process (Fig. 1C).
Capn6 modulates osteoclast spreading
To investigate its role in osteoclast development, we retrovirally
transduced wild-type (WT) BMMs with Capn6 or empty vector
(Fig. 2A). The cells were cultured in M-CSF and RANKL, and
osteoclasts were identified by TRAP activity. Capn6 over-
expression yields osteoclasts that are spread and larger than
their vector-transduced counterparts (Fig. 2B).
We explored the role of endogenous Capn6 in osteoclast
development by transducing BMMs with lentivirus carrying
Capn6 small hairpin RNAs (shRNA) (denoted as Capn6-sh1 and
Capn6-sh2) or control luciferase shRNA (Luc-sh). The shRNAs
substantially reduce Capn6 mRNA and/or protein (Fig. 2C).
Establishing specificity, Capn6 knockdown does not alter the
abundance of classic calpain mRNA.
We next determined the impact of altered Capn6 expression
on osteoclast morphology. Thus Luc-sh-, Capn6-sh1-, and Capn6-
sh2-bearingBMMswerecultured withM-CSFand25 or50ng/mL
ofRANKLfor5daysandstainedforTRAPactivity.WhereasLuc-sh
transductants form characteristicwell-spread osteoclasts, Capn6-
Fig. 1. Expression of Capn6 is regulated by dexamethasone and
enhanced during osteoclast development. (A) BMMs were cultured in
M-CSF and RANKL for 3 days to commit them to the osteoclast pheno-
type. The cells then were maintained without or with DEX (100 nM) for
theindicated times.Capn6expression was determinedby RT-PCR(left)o r
immunoblotting (right). (B, C) BMMs were cultured in M-CSF (20ng/mL)
and RANKL (100ng/mL) with time. (B) Calpain family member mRNA was
determined by RT-PCR. (C) Capn6 expression was analyzed by immuno-
blotting. Cathepsin K (CathK)o rc-Src serves as a positive control for
osteoclastogenesis and GAPDH or b-actin as loading control.
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with a ‘‘crenated’’ appearance similar to those with established
cytoskeletal defects (Fig. 2D, E).
To determine if morphologic changes induced by Capn6
excess or deficiency reflect altered differentiation and/or fusion
of osteoclast precursors, we assessed mRNA of relevant proteins
during the osteoclastogenic process. Neither increased Capn6
nor its knockdown has an impact on gene expression of the
fusion marker DC-STAMP or a variety of indicators of osteoclast
differentiation (Fig. 2F, G). Furthermore, overexpression or
knockdown of Capn6 does not have an impact on the number
of viable osteoclast precursors exposed to various concentra-
tions of M-CSF (Fig. 2H, I).
Capn6 modulates cytoskeletal organization
Given that alteredexpressionofCapn6 doesnotaffect osteoclast
fusion or differentiation, we focused on function, particularly in
thecontextofthecytoskeleton.TodetermineifCapn6associates
with actin rings of bone-resorptive cells, osteoclasts were
generated, on coverslips, from BMMs transduced with pMX or
Flag-tagged Capn6. Immunostaining with anti-actin and anti-
Flag antibodies reveals that Capn6 localizes to the actin ring,
suggesting that it may participate in cytoskeletal organization
(Fig. 3A). To confirm that such is the case, we generated
osteoclasts on bone slices in M-CSF and RANKL for 5 days and
stained the actin cytoskeleton with TRITC-conjugated phalloidin.
Reflecting enhanced spreading, osteoclasts transduced with
Capn6containlargeractinringsthancontrolosteoclasts(Fig.3B).
Further establishing that the enzyme organizes the cytoskeleton,
Capn6-silenced osteoclasts failed to generate rings from actin
clusters (Fig. 3C, D). Thus Capn6 excess enhances cytoskeletal
organization, whereas its deficiency is inhibitory.
Capn6 regulates microtubule distribution and acetylation
During bone resorption, actin clusters mature into rings, a
process that depends on functioning microtubules.
(28) To
determine if endogenous Capn6 interacts with microtubules,
tubulin was precipitated from mature osteoclasts. Immunoblot-
ting with anti-Capn6 antibody documented that Capn6
associates with microtubules in osteoclasts (Fig. 4A). In
confirmation of these data, immunostaining demonstrated that
Capn6 localizes to the microtubule network (Fig. 4B).
To investigate the functional implications of this association,
we assessed the impact of Capn6 knockdown on microtubule
organization. As seen in Fig. 4C, cells transduced with Luc-sh
contain radial microtubules enriched in the vicinity of the actin
ring. In contrast, the microtubule network of Capn6-sh-bearing
osteoclasts is irregular and not juxtaposed to the cell’s periphery.
Similarly, Capn6 knockdown osteoclasts contain fewer nocoda-
zole-resistantstablemicrotubulesthancellstransducedwithLuc-
sh (Fig. 4D). Conversely, nocodazole-resistant stable microtu-
bules are enhanced in Capn6-overexpressing osteoclasts
(Fig. 4E).
Microtubules in mature osteoclast are acetylated, which, in
turn, maintains their stability.
(28) Because Capn6 overexpression
enhances microtubule acetylation and stability in HeLa cells,
(25)
we asked whether the same holds in osteoclasts. In fact, Capn6-
Fig. 2. Capn6regulatescellspreading.(A,B)BMMsweretransducedwith
pMX vector containing Flag or Flag-Capn6. (A) Capn6 expression was
analyzed by RT-PCR (left) or immunoblotting (right). (B) Osteoclasts were
generated with 25ng/mL of RANKL and M-CSF and stained for TRAP
activityafter4days.(C–E)BMMsweretransducedwithLuc-sh-(control)or
Capn6-shRNA (Capn6-sh1 and Capn6-sh2) and cultured in M-CSF and
RANKL. (C) Capn6 and classic calpain mRNAs were determined by RT-PCR
(left) or Capn6 protein expression by immunoblotting (right). (D) Cells
were stained for TRAP activity after 5 days. Arrows indicate nonspread
TRAP
þ osteoclasts. (E) Statistical analysis of characteristic spread TRAP
þ
multinucleated cells per well.
 p<0.001. ( F) BMMs were transduced with
pMXbearingFlagorFlag-Capn6andculturedfor4dayswithM-CSFalone
(day0)orM-CSFandRANKL(days2 and4).RT-RCRwasperformedforthe
expression of fusion or osteoclastogenic markers. (G) BMMs were trans-
duced with Luc-sh or Capn6-sh1 and cultured as described in panel F. RT-
PCR analysis was performed. GAPDH serves as loading control. (H) BMMs
weretransducedwithpMX bearingFlagor Flag-Capn6.Equalnumbersof
BMMs were cultured with the indicated concentrations of M-CSF for 3
days. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium (MTS) assay was performed by measuring
optical density (OD) values at 490nm. (I) Equal numbers of BMMs
transduced with Luc-sh or Capn6-sh1 were cultured with the indicated
concentrations of M-CSF. After 3 days, MTS assay was performed.
660 Journal of Bone and Mineral Research HONG ET AL.transduced osteoclasts contain an abundance of acetylated
tubulin relative to control (Fig. 4F). This morphologic observation
is confirmed by immunoblotting total tubulin and its acetylated
form in the same cells (Fig. 4G). Conversely, tubulin acetylation in
Capn6 knockdown osteoclasts is reduced substantially (Fig. 4H).
GCs inhibit microtubule stability and acetylation in
osteoclasts
Because GCs suppress osteoclast spreading and actin ring
formation,
(29) we examined the effects of the steroid on
osteoclast microtubules. To this end, we committed BMMs to
the osteoclast phenotype in the presence of M-CSF and RANKL
for3days. Thecellswere treatedwith vehicle orDEX for2 days in
osteoclastogenic medium. While the control cells contain
characteristic radial microtubules, similar to the Capn6 knock-
down osteoclasts, the network of those treated with DEX was
irregular (Fig. 4I). We also found that DEX-treated osteoclasts
possess few nocodazole-resistant microtubules (Fig. 4J). This
DEX-mediated microtubule instability is confirmed by immuno-
blots showing the reduced acetylated tubulin in steroid-exposed
osteoclasts (Fig. 4K).
Capn6 and GCs regulate b3-integrin expression
The avb3-integrin is key to organizing the osteoclast cytoske-
leton. In fact, both Capn6- and b3-integrin-deficient osteoclasts
enjoy a similar phenotype in that they fail to spread, yielding the
common‘‘crenated’’ appearance inducedby deletionofavariety
of cytoskeleton-regulating molecules. Suggesting that avb3-
integrin mediates Capn6’s effects on the osteoclast, expression
of b3-integrin protein is reduced in Capn6-sh1-transduced cells
(Fig. 5A).
DEX decreases the expression of b3-integrin protein (Fig. 5B).
Alternatively, b3-integrin mRNA is not altered by either Capn6
knockdown or DEX, indicating a posttranscriptional event
(Fig. 5C, D).
Capn6 regulates bone resorption
Cytoskeletalalterationintheosteoclastistypicallymirroredbyits
resorptive capacity, and we asked whether the same obtains in
the context of Capn6. Thus we generated control and Capn6-
overexpressing or -deleted osteoclasts on bone. Reflecting their
‘‘superspread’’ appearance, bone degradation by Capn6-trans-
ducedpolykaryonsisenhanced,asevidencedbyabundant,large
pitsand,mostimportantly,releaseofcollagentypeIdegradation
products (Fig. 6A, B). Incontrast, the sameassays established that
Capn6-silenced cells inefficiently resorb bone (Fig. 6C, D).
Capn6 overexpression reverses GC-mediated disruption
of cytoskeletal organization
To determine whether ectopic expression of Capn6 rescues the
inhibitory effect of GCs on the osteoclast cytoskeleton, we
retrovirally transduced BMMs with pMX empty vector or Capn6
and committed them to the osteoclast phenotype in M-CSF and
RANKL for 3days. Thecells then weretreated with vehicle orDEX
for 2 days in osteoclastogenic medium and stained for TRAP
activity. Capn6 overexpression rescues DEX-mediated disruption
of the osteoclast cytoskeleton (Fig. 7).
Discussion
GCtreatmentisthesecondmost commoncauseofosteoporosis,
reflecting, in part, direct inhibition of the osteoblast. GCs,
however, potently inhibit osteoclasts, and their chronic use is
characterized by suppressed bone turnover. Thus DEX also
blunts osteogenesis by arresting the initiating event of
remodeling, namely, osteoclast activation. The consequences
of GC-attenuated remodeling are not only osteoporosis but also
compromised bone quality, eventuating in diminished mechan-
ical stability per unit of skeletal mass.
(30) Steroid-suppressed
resorption, therefore, likely predisposes to fracture.
Bone degradation is modulated by altering the abundance or
matrix-degrading capacity of osteoclasts. While GCs acutely
Fig. 3. Alteration of Capn6 expression regulates actin ring formation.
BMMs were transduced with pMX vector containing Flag or Flag-Capn6
andculturedoncoverslips (A)orboneslices(B) for5 dayswithM-CSFand
RANKL. (A) Nuclei, F-actin, and Flag-Capn6 were stained with Hoechst
(blue), TRITC-conjugated phalloidin (red), and anti-flag antibody (green),
respectively, and detected by confocal microscopy. Untransfected cells
were stained as a control. Scale bars¼50mm. (B) Actin ring formation
wasexaminedbyimmunofluorescenceafterTRITC-phalloidinstaining.(C,
D) BMMstransduced with Luc-sh or Capn6-sh1 were seeded on bone and
exposed to M-CSF and RANKL for 6 days. (C) The cells were fixed and
stainedwith TRITC-phalloidintovisualizeactinrings.(D) Quantification of
percentage of osteoclasts containing actin rings (white bars) or clusters
(black bars).
 p<0.001.
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longevity of the differentiated polykaryon.
(29,31) These compen-
sating properties in combination yield no change in osteoclast
number. On the other hand, DEX disrupts the osteoclast
cytoskeleton and in so doing attenuates the cell’s bone-
resorptive capacity.
(29) Given the clinical implications of
steroid-suppressed osteoclast function, we turned to the means
by which DEX exerts its anti-resorptive effects.
Our efforts were initiated by microarray analysis of GC- and
vehicle-treated osteoclasts, wherein 387 genes are suppressed,
Fig. 4. Capn6andDEXmodulateosteoclastmicrotubuledistributionandacetylation.(A,B)EndogenousCapn6colocalizestothemicrotubule.BMMswere
cultured in M-CSF and RANKL for 4 days. (A) Osteoclast lysates were immunoprecipitated with anti-tubulin antibody and subjected to immunoblotting
withtheindicatedantibodies.(Lane1)Proteinbeadswithanti-tubulinAbbutwithoutcellextract(negativecontrol).(Lane2)Proteinbeadswithcellextract
but without Ab (negative control). (Lane 3) Protein beads with cell extract and Ab. (B) Osteoclasts were stained with anti-Capn6 (red) and anti-tubulin
(green) antibody. (C, D) BMMs were transduced with Luc-sh or Capn6-sh1 and cultured on coverslips in M-CSF and RANKL for 5 days. (C) Cells were stained
with Hoechst (blue), TRITC-conjugated phalloidin (red), and anti-tubulin (green) antibody. (D) Osteoclasts were treated with 2mM nocodazole for 1 hour,
fixed, and labeled. (E–G) BMMs were transduced with pMX containing Flag or Flag-Capn6. Osteoclasts were generated on coverslips. (E) The cells were
fixed and labeled. ( F) Osteoclasts were stained with TRITC-conjugated phalloidin (red) and anti-acetylated tubulin (green) antibody. (G) Osteoclast lysates
wereimmunoblottedwiththeindicatedantibodies. Theratioofacetylatedtubulinto b-actinwasdeterminedbydensitometry. (H) BMMstransducedwith
Luc-sh or Capn6-sh1 were cultured in M-CSF and RANKL. Osteoclast lysates were immunoblotted with the indicated antibodies. (I–K) Dexamethasone
inhibits osteoclast microtubule stability. BMMs were cultured in M-CSF and RANKL for 3 days to commit them to the osteoclast phenotype. The cells then
were maintained without or with DEX (100 nM) for 2 days. (I) Osteoclasts were labeled with TRITC-phalloidin and anti-tubulin antibodies. (J) Mature
osteoclasts were treated with 2mM nocodazole for 1 hour, fixed, and labeled. (K) Osteoclast lysates were immunoblotted with the indicated antibodies.
The ratio of acetylated tubulin to b-actin was determined by densitometry. All scale bars indicate 50mm.
662 Journal of Bone and Mineral Research HONG ET AL.but most prominently Capn6. Unlike the classic family members,
Capn1 (m-calpain) and Capn2 (m-calpain), which are constitutive
and unchanged in osteoclasts and their undifferentiated
precursors, Capn6 is substantially upregulated during the
osteoclastogenic process. Thus Capn6 presents as a candidate
mediator of osteoclast function and a GC target in the mature
cell.
Unlike the suppressive effects of GCs on BMMs, Capn6
abundance or deficiency does not alter the numbers of viable
osteoclast precursors. Thus the Capn6 is unlikely to modulate
DEX’s anti-proliferative effects on BMMs. Like the steroid,
however, Capn6 does not retard differentiation but regulates
the capacity of osteoclasts to spread, a manifestation of actin
organization. Capn6 overexpression promotes a ‘‘superspread’’
appearance of the polykaryon, with enlarged actin rings and
enhanced capacity to resorb bone. A reciprocal phenotype is
achieved by silencing the Capn6 gene, yielding a dominance of
nonspread hyporesorptive cells that lack actin rings. These
observations establish that Capn6 is a regulator of the osteoclast
cytoskeleton, which is in keeping with its localization within the
sealing zone. Furthermore, Capn6-deficient osteoclasts resemble
those treated with GCs, buttressing the hypothesis that the
steroid exerts its effects via Capn6 inhibition.
While the osteoclast cytoskeleton is unique in structure, like
that of all cells, it remodels with function. Thus actin is diffusely
distributed throughout the cytoplasm in the nonresorptive,
motile state and polarizes into the sealing zone during bone
degradation. The generation of large actin rings and lacunae by
osteoclasts overexpressing Capn6 and the clustered actin and
scattered small pits appearing in the face of its suppression
confirm that Capn6 modulates the cell’s cytoskeleton pari passu
with resorptive function.
Fig. 5. Capn6 knockdown or dexamethasone suppresses b3-integrin
protein expression. (A) BMMs were transduced with Luc-sh or Capn6-
sh1 and cultured in M-CSF and RANKL for 4 days. Lysates were immuno-
blotted for b3-integrin subunit. Actin serves as loading control. (B) BMMs
were cultured in M-CSF and RANKL for 3 days. DEX (100 nM) or vehicle
was added for an additional 24hours. Lysates were immunoblotted for
b3-integrin subunit. Actin serves as loading control. (C) Luc-sh- or Capn6-
sh1-transduced BMMs were cultured in M-CSF (BMMs) or M-CSF and
RANKL (OCs) for 4 days. b3-Integrin mRNA expression was determined by
RT-PCR. GAPDH serves as loading control. (D) BMMs were cultured for
3 days in M-CSF and RANKL. DEX (100 nM) was added for an additional 6
or 16 hrs. b3-Integrin mRNA expression was determined by RT-PCR.
GAPDH serves as loading control. Relative b3-integrin expression was
determined by densitometry.
Fig. 6. Capn6 modulates bone-resorptive activity. (A, B) BMMs were
transduced with pMX containing Flag or Flag-Capn6 and cultured on
bone slices with M-CSF and RANKL. (A) After 5 days, osteoclasts were
removed, and resorption pits were visualized with peroxidase-conju-
gated wheat germ agglutinin. (B) Medium was collected and assayed for
CTX-I content by ELISA.
 p<0.05. (C, D) BMMs transduced with Luc-sh or
Capn6-sh1 were cultured on bone in the presence of M-CSF and RANKL
for 6 days. (C) Lacuna formation was visualized. (D) Total bone resorption
was determined by CTX-I ELISA of culture medium.
  p<0.001.
Fig. 7. Overexpression of Capn6 rescues the inhibitory effect of dexa-
methasoneon osteoclast cytoskeleton.BMMsweretransducedwithpMX
vector containing Flag or Flag-Capn6 and cultured in M-CSF and RANKL
for 3 days to commit them to the osteoclast phenotype. The cells then
were maintained without or with DEX (100 nM) for 2 days. (A) The cells
were stained for TRAP activity. (B) Statistical analysis of characteristic
spread TRAP
þ multinucleated cells per well.
 p<0.005.
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integrin heterodimer when the cell contacts bone. The liganded
integrin initiates a signaling pathway involving c-Src, Syk, ITAM-
adaptorproteins,SLP-76,andVav-3thatinducesGTPasessuchas
Rac to transit from their inactive GDP-bound state to their active
GTP-bound conformation. The suppressive effect of Capn6
deletion on b3-integrin subunit expression therefore likely
contributes to the associated cytoskeletal disorganization.
Recent evidence indicates, however, that integrin-mediated
actin ring formation may involve an additional major compo-
nent, namely, microtubules.
Microtubules are key regulators of the mitotic machinery
governing spindle position and polarity. In addition, they
participate in actin filament distribution within the contractile
ring whose action completes cell division. The functionality of
microtubules depends on cycling between their acetylated,
stable and deacetylated, destabilized states. In keeping with a
tethering of integrin- and microtubule-mediated actin remodel-
ing, avb3-integrin occupancy acetylates tubulin.
(32) Deletion of
the integrin’s target, Pyk2, exerts the opposite effect and yields
abnormal actin rings, as occurs in avb3-integrin-deficient
polykaryons. Finally, failure to acetylate or deacetylate tubulin
enhances bone mass presumably owing to osteoclast dysfunc-
tion.
(5,33)
We found that Capn6, which is inhibited by GCs, binds to and
acetylates osteoclast tubulin, thereby stabilizing the cell’s
microtubules. These stabilized microtubules are juxtaposed on
the actin ring and radiate toward the cell’s center. Capn6
overexpression accentuates this radial distribution of micro-
tubules. Alternatively, downregulation of the Capn6 removes
deacetylated tubulin from the periphery and alters its
filamentous appearance. The acetylation and deacetylation
induced by the respective increase and decrease in Capn6 are
mirrored by the cell’s resorptive activity.
Maintenance of tubulin’s acetylated state in the osteoclast is
proposed to involve RhoA activation, which, in turn, blunts
histone deacetylase 6 (HDAC6). GCs, however, suppress Capn6
but inhibit RhoA activation. Whereas HDAC6 inhibition may
participate in microtubule-mediated osteoclast activity, the fact
that deletion of the deacetylase in mice eventuates in a mild
bone phenotype
(33) indicates that other mechanisms of
stabilization exist.
Our studies and others areconsistent withadynamic modelof
osteoclast function in which the acetylated state of tubulin plays
acentralrole.Duringthebone-degradingphaseoftheresorptive
cycle, wherein polarized actin ring formation is required,
microtubules must be acetylated and stabilized. On cessation
of matrix resorption and induction of motility, actin transits into
its clustered conformation, and microtubules are deacetylated.
The similarity of DEX-treated osteoclasts and those with
deacetylaed tubulin owing to Capn6 downregulation suggests
that inhibition of the Capn6 may be a component of the
resorption-inhibiting properties of the steroid.
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